0000899243-20-007821.txt : 20200310
0000899243-20-007821.hdr.sgml : 20200310
20200310211508
ACCESSION NUMBER: 0000899243-20-007821
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200302
FILED AS OF DATE: 20200310
DATE AS OF CHANGE: 20200310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Chirag K.
CENTRAL INDEX KEY: 0001738701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 20703732
MAIL ADDRESS:
STREET 1: C/O AMNEAL PHARMACEUTICALS LLC
STREET 2: 400 CROSSING BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-02
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001738701
Patel Chirag K.
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD, 3RD FLOOR
BRIDGEWATER
NJ
08807
1
1
1
0
President, Co-CEO & Director
Class A Common Stock
2020-03-02
4
P
0
34641
3.87
A
40748
D
Class A Common Stock
2020-03-03
4
P
0
156421
3.88
A
197169
D
Class A Common Stock
2020-03-04
4
P
0
58938
3.97
A
256107
D
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.805 to $3.92, inclusive.
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.75 to $4.00, inclusive.
The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.00, inclusive.
The reporting person undertakes to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares transacted at each price, with respect to all transactions reported on this Form 4.
/s/ Meredith Cook, Attorney-in-Fact
2020-03-10